QHSLab (USAQ) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, Address Line Three	West Palm
Entity Address, City or Town	Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Trading Symbol	USAQ
Title of 12(g) Security	Common Stock, $0.0001 Par Value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,735,508

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 50,240	$ 178,694
Accounts receivable, net	83,550	47,734
Inventory	38,954	51,840
Prepaid expenses and other current assets	4,246	7,310
Total current assets	176,990	285,578
Non-current assets:
Capitalized software development costs, net	111,695	167,543
Intangible assets, net	1,450,248	1,504,332
Total assets	1,738,933	1,957,453
Current Liabilities:
Accounts payable	220,237	85,743
Other current liabilities	159,395	116,774
Loans payable, current portion	412,781	342,391
Convertible notes payable	1,246,000	1,161,918
Total current liabilities	2,038,413	1,706,826
Non-current liabilities:
Loans payable, non-current portion		174,382
Total non-current liabilities		174,382
Total liabilities	2,038,413	1,881,208
Commitments and contingencies (Note 13)
Stockholders’ (Deficit) Equity:
Common stock, 900,000,000 shares authorized, $0.0001 par value; 9,315,508 shares issued and outstanding	932	932
Additional paid-in capital	3,595,837	3,589,837
Accumulated deficit	(3,896,621)	(3,514,896)
Total stockholders’ (deficit) equity	(299,480)	76,245
Total liabilities and stockholders’ (deficit) equity	1,738,933	1,957,453
Series A Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock, value	108	108
Series A-2 Preferred Stock [Member]
Stockholders’ (Deficit) Equity:
Preferred stock, value	$ 264	$ 264

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.25
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	9,315,508	9,315,508
Common stock, shares outstanding	9,315,508	9,315,508
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	1,080,092	1,080,092
Preferred stock, shares outstanding	1,080,092	1,080,092
Series A-2 Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	2,644,424	2,644,424
Preferred stock, shares outstanding	2,644,424	2,644,424

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 336,407	$ 269,323	$ 1,093,974	$ 975,469
Cost of revenue	146,897	143,716	490,294	490,965
Gross profit	189,510	125,607	603,680	484,504
Operating expenses:
Sales and marketing	114,019	154,620	366,055	387,687
General and administrative	47,277	107,965	205,799	321,573
Research and development	45,419	48,405	169,489	135,998
Amortization	18,028	18,028	54,084	54,084
Total operating expenses	224,743	329,018	795,427	899,342
Net operating loss	(35,233)	(203,411)	(191,747)	(414,838)
Other income and (expense):
Interest expense	(48,581)	(106,704)	(192,268)	(362,946)
Other income	1,371		2,290
Loss on extinguishment of debt				(2,020)
Net loss	$ (82,443)	$ (310,115)	$ (381,725)	$ (779,804)
Basic net loss per share	$ (0.01)	$ (0.03)	$ (0.04)	$ (0.09)
Diluted net loss per share	$ (0.01)	$ (0.03)	$ (0.04)	$ (0.09)
Weighted average shares outstanding: (Basic)	9,315,508	9,068,225	9,315,508	8,889,836
Weighted average shares outstanding: (Diluted)	9,315,508	9,068,225	9,315,508	8,889,836

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Common Stock [Member]	Unearned Stock Compensation [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 108	$ 264	$ 876	$ (6,968)	$ 3,348,681	$ (2,518,895)	$ 824,066
Balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Stock-based compensation expense					8,920		8,920
Net loss						(190,304)	(190,304)
Shares issued for services				3,484			3,484
Conversion of notes payable			$ 6		27,919		27,925
Conversion of notes payable, shares			59,415
Warrants issued with convertible note payable					2,020		2,020
Balance at Mar. 31, 2022	$ 108	$ 264	$ 882	(3,484)	3,387,540	(2,709,199)	676,111
Balance, shares at Mar. 31, 2022	1,080,092	2,644,424	8,815,508
Balance at Dec. 31, 2021	$ 108	$ 264	$ 876	(6,968)	3,348,681	(2,518,895)	824,066
Balance, shares at Dec. 31, 2021	1,080,092	2,644,424	8,756,093
Net loss							(779,804)
Balance at Sep. 30, 2022	$ 108	$ 264	$ 932		3,583,594	(3,298,699)	286,199
Balance, shares at Sep. 30, 2022	1,080,092	2,644,424	9,315,508
Balance at Mar. 31, 2022	$ 108	$ 264	$ 882	(3,484)	3,387,540	(2,709,199)	676,111
Balance, shares at Mar. 31, 2022	1,080,092	2,644,424	8,815,508
Stock-based compensation expense					8,921		8,921
Net loss						(279,385)	(279,385)
Shares issued for services				3,484			3,484
Balance at Jun. 30, 2022	$ 108	$ 264	$ 882		3,396,461	(2,988,584)	409,131
Balance, shares at Jun. 30, 2022	1,080,092	2,644,424	8,815,508
Stock-based compensation expense					6,000		6,000
Net loss						(310,115)	(310,115)
Conversion of notes payable			$ 25		49,975		50,000
Conversion of notes payable, shares			250,000
Warrants issued with convertible note payable					81,183		81,183
Share purchase			$ 25		49,975		50,000
Share purchase, shares			250,000
Balance at Sep. 30, 2022	$ 108	$ 264	$ 932		3,583,594	(3,298,699)	286,199
Balance, shares at Sep. 30, 2022	1,080,092	2,644,424	9,315,508
Balance at Dec. 31, 2022	$ 108	$ 264	$ 932		3,589,837	(3,514,896)	76,245
Balance, shares at Dec. 31, 2022	1,080,092	2,644,424	9,315,508
Stock-based compensation expense					6,000		6,000
Net loss						(192,555)	(192,555)
Balance at Mar. 31, 2023	$ 108	$ 264	$ 932		3,595,837	(3,707,451)	(110,310)
Balance, shares at Mar. 31, 2023	1,080,092	2,644,424	9,315,508
Balance at Dec. 31, 2022	$ 108	$ 264	$ 932		3,589,837	(3,514,896)	76,245
Balance, shares at Dec. 31, 2022	1,080,092	2,644,424	9,315,508
Net loss							(381,725)
Balance at Sep. 30, 2023	$ 108	$ 264	$ 932		3,595,837	(3,896,621)	(299,480)
Balance, shares at Sep. 30, 2023	1,080,092	2,644,424	9,315,508
Balance at Mar. 31, 2023	$ 108	$ 264	$ 932		3,595,837	(3,707,451)	(110,310)
Balance, shares at Mar. 31, 2023	1,080,092	2,644,424	9,315,508
Net loss						(106,727)	(106,727)
Balance at Jun. 30, 2023	$ 108	$ 264	$ 932		3,395,837	(3,814,178)	(217,037)
Balance, shares at Jun. 30, 2023	1,080,092	2,644,424	9,315,508
Net loss						(82,443)	(82,443)
Balance at Sep. 30, 2023	$ 108	$ 264	$ 932		$ 3,595,837	$ (3,896,621)	$ (299,480)
Balance, shares at Sep. 30, 2023	1,080,092	2,644,424	9,315,508

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (381,725)	$ (779,804)
Adjustments to reconcile net loss to net cash from operating activities:
Allowance for doubtful accounts	5,992	9,173
Amortization	109,932	91,315
Amortization of debt and warrant issuance costs	84,082	267,889
Stock-based compensation	6,000	23,842
Shares issued for services		6,968
Loss on extinguishment of debt		2,020
Changes in operating assets and liabilities:
Accounts receivable	(41,808)	3,207
Inventory	12,886	(32,219)
Prepaid expenses and other current assets	3,064	(26,622)
Accounts payable	134,494	129,625
Other current liabilities	42,621	23,401
Cash flows from operating activities	(24,462)	(281,205)
Investing activities:
Capitalized software		(37,119)
Cash flows from investing activities		(37,119)
Financing activities:
Proceeds from sales of common stock		50,000
Issuance of convertible notes payable		400,000
Proceeds of loan borrowings	162,000	128,500
Repayments of loan borrowings	(265,992)	(279,097)
Payment of debt issuance costs		(30,000)
Cash flows from financing activities	(103,992)	269,403
Change in cash	(128,454)	(48,921)
Cash and cash equivalents – beginning of year	178,694	286,855
Cash and cash equivalents - end of period	50,240	237,934
Supplemental disclosures of cash flow activity:
Cash paid for interest	36,930	55,939
Cash paid for taxes
Supplemental noncash investing and financing activity:
Debt and accrued interest converted to shares of common stock		77,925
Warrants issued in conjunction with convertible note payable		$ 81,183

The Company

The Company	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1. The Company QHSLab, Inc. (the “Company” or the “Registrant”) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc. The Company is a medical device technology and software-as-a-service (“SaaS”) company focused on enabling primary care physicians (“PCP’s”) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, has negative operational cash flows and only began recognizing revenues in the fourth quarter of fiscal 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company’s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Note 3. Basis of Presentation The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes included in our Annual Report on Form 10- K for the year ended December 31, 2022. The accounting policies are described in the “Notes to the Consolidated Financial Statements” in the 2022 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. Reclassifications Certain reclassifications were made to the prior condensed consolidated financial statements to conform to the current period presentation. There was no change to the previously reported net loss. Accounting Policies Use of Estimates Principles of Consolidation Cash and Cash Equivalents Accounts Receivable 18.9 14.2 Inventories Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 223,390 as of September 30, 2023 and December 31, 2022. The Company completed testing of its internally-developed software application (“QHSLab platform”) at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During the three months ended September 30, 2023 and 2022 there was $ 18,616 of amortization recognized. During the nine months ended September 30, 2023 and 2022 there was $ 55,848 and $ 37,231 of amortization recognized, respectively. There were no impairments recognized during the nine months ended September 30, 2023 and the year ended December 31, 2022. Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets. Convertible Notes Payable Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Revenue Recognition Revenue from Contracts with Customers To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (“SaaS”) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract. Research and Development 45,419 48,405 169,489 135,998 Stock-based Compensation Share Based Payment Earnings Per Common Share Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 3,896,621 begin to expire in 2027 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2023
Credit Loss [Abstract]
Accounts Receivable	Note 4. Accounts Receivable Accounts receivable is recorded in the condensed consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation. Accounts receivable is presented net of an allowance for doubtful accounts. During the year ended December 31, 2022, the Company established an allowance for doubtful accounts that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows: Schedule of Accounts Receivable September 30, December 31, Accounts receivable $ 97,772 $ 55,964 Allowance for doubtful accounts (14,222 ) (8,230 ) Accounts receivable, net $ 83,550 $ 47,734

Capitalized Software and Intang

Capitalized Software and Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized Software and Intangible Assets	Note 5. Capitalized Software and Intangible Assets Non-current assets consist of the following at September 30, 2023 and December 31, 2022: Schedule of Intangible Assets Estimated Useful Life (in years) September 30, December 31, Capitalized software 3.0 $ 223,390 $ 223,390 Accumulated amortization (111,695 ) (55,847 ) Capitalized software, net $ 111,695 $ 167,543 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible assets $ 1,612,500 $ 1,612,500 Accumulated amortization (162,252 ) (108,168 ) Intangible assets, net $ 1,450,248 $ 1,504,332 Capitalized software represents the development costs for internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. As of September 30, 2023 and December 31, 2022 there was $ 111,695 and $ 55,847 of accumulated amortization expense, respectively. Amortization related to the QHSLab platform was $ 18,616 for the three months ended September 30, 2023 and 2022, and is recorded within cost of revenue on the Company’s condensed consolidated statements of operations. Amortization was $ 55,848 and $ 37,231 for the nine months ended September 30, 2023 and 2022, respectively. There were no impairments recognized during the nine months ended September 30, 2023 and the year ended December 31, 2022. The intangible assets represent the value the Company paid to acquire the trademark “AllergiEnd”, the web domain “AllergiEnd.com” along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 Business Combination, Related Issues, Initial Measurement. Intangibles, General Intangibles Other Than Goodwill 18,028 54,084

Loans Payable

Loans Payable	9 Months Ended
	Sep. 30, 2023
Loans Payable
Loans Payable	Note 6. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (“MedScience”) (See Note 5 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 386,735 426,451 On April 21, 2023, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 162,000 20,538 October 2024 40,821

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7. Convertible Notes Payable Convertible notes payable at September 30, 2023 and December 31, 2022, consist of the following: Schedule of Convertible Notes Payable September 30, 2023 December 31, 2022 Note 1 – Shareholder $ 100,000 $ 100,000 Note 2 – Mercer Note 706,000 706,000 Note 3 – Mercer Note #2 440,000 440,000 Total 1,246,000 1,246,000 Debt discount and issuance costs - (84,082 ) Total convertible notes payable 1,246,000 1,161,918 Less: current portion 1,246,000 1,161,918 Non-current portion $ - $ - Note 1 – Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 10 September 30, 2022 The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of December 31, 2023 at the option of the holder using the same conversion calculation 24,000 16,521 Note 2 – Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the “Note”) in the principal amount of $ 806,000 930,000 750,000 The principal amount of the Note and all interest accrued thereon was initially payable on August 10, 2022, and is secured by a lien on substantially all of the Company’s assets. The Note provides for interest at the rate of 5 0.65 On November 11, 2021, Mercer Street Global Opportunity Fund, LLC, converted $ 50,000 806,000 76,923 0.65 The 930,000 three years 1.25 As a result of the issuance of a $ 440,000 0.20 806,000 0.20 50,000 806,000 250,000 0.20 On October 17, 2022, and again on July 27, 2023 and November 10, 2023, the Company received notice from the manager of Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under the $ 806,000 806,000 5 As of September 30, 2023, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $ 706,000 806,000 78,573 0 806,000 52,171 0 Note 3 – Effective July 19, 2022, the Company entered into a Securities Purchase Agreement with Mercer Fund pursuant to which it issued an Original Issue Discount Secured Convertible Promissory Note (the “$440,000 Note”) in the principal amount of $ 440,000 550,000 400,000 The principal amount of the $ 440,000 440,000 5 0.20 440,000 440,000 The $ 440,000 440,000 440,000 440,000 On July 27, 2023 and again on November 10, 2023, the Company received notice from the manager of the Mercer Fund, LLC that it agreed to forebear from exercising any rights it might have as a result of any defaults under the Second OID Note and the related documents between the Company and the Fund, provided that it reserved all of its rights. The 550,000 0.50 440,000 The Registration Rights Agreement requires the Company to file with the Securities and Exchange Commission within 60 days following the closing of the issuance of the $ 440,000 440,000 440,000 The Company accounts for the allocation of its issuance costs to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital. The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the $ 440,000 440,000 26,219 0 440,000 9,764 61,836 22,247

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Preferred Stock	Note 8. Preferred Stock Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $ 0.25 0.05 Series A-2 Preferred Stock On December 30, 2021, the Board of Directors of the Company authorized the issuance of 2,644,424 286,078 The shares of Series A-2 Preferred Stock have a stated value of $ 0.16 0.16 Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company’s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.

Loss Per Common Share

Loss Per Common Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Loss Per Common Share	Note 9. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Stock options 1,100,000 1,100,000 1,100,000 1,100,000 Stock warrants 1,494,854 1,576,647 1,494,854 1,576,647 Total shares excluded from calculation 2,594,854 2,676,647 2,594,854 2,676,647 Antidilutive securities 2,594,854 2,676,647 2,594,854 2,676,647

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 10. Stock-based Compensation During the nine months ended September 30, 2023 and 2022, there was $ 6,000 and $ 23,842 , respectively, in stock-based compensation associated with stock options included in Research and development expense. During the three months ended September 30, 2023 and 2022, there was $ 0 and $ 6,000 , respectively, in stock-based compensation associated with stock options included in Research and development expense. Additionally, there was expense associated with shares issued for services. During the nine months ended September 30, 2023 and 2022, there was $ 0 and $ 6,968 , respectively, in General and administrative expense associated with shares issued for services. There were no no As of September 30, 2023, all compensation related to the 1,100,000 Options outstanding at September 30, 2023 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 450,000 $ 0.65 December 31, 2025 Total 1,100,000 1,100,000 Warrants outstanding at September 30, 2023 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July 18, 2025 Total 1,494,854 1,494,854 During the nine months ended September 30, 2023, 81,793

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Convertible notes payable, related party: Preferred Stock, related party:

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes For the nine months ended September 30, 2023 and the year ended December 31, 2022, the Company did not record a tax provision as the Company did not earn any taxable income in either period and maintains a full valuation allowance against its net deferred tax assets.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13. Commitments and Contingencies On February 9, 2021, the Company entered into a Receivables Purchase and Security Agreement (“Factoring Agreement”) with a Factoring Company. The Factoring Agreement has an initial term of one year Under the terms of the agreement, designated receivables are sold for periodic advances of up to $ 150,000 10 1.8 The balance of outstanding invoices that the Factoring Company may assign back to the Company if not collected within 90 days is included in the Company’s Accounts Receivable balance with the amounts received, net of reserves held, included with other current liabilities on the condensed consolidated balance sheets. The Factoring Agreement was cancelled as of August 3, 2023 so no amounts are outstanding as of September 30, 2023. The net amount of $ 3,098 There are no pending or threatened legal proceedings as of September 30, 2023. The Company has no non-cancellable operating leases.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events On October 4, 2023, Mercer Street Global Opportunity Fund, LLC, converted $ 10,500 806,000 420,000 0.025 On October 5, 2023, the Company entered into a fixed-fee loan with its merchant bank and received $ 226,700 28,463 April 2025

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 18.9 14.2
Inventories	Inventories
Capitalized Software Development Costs	Capitalized Software Development Costs Internal-Use Software The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 223,390 as of September 30, 2023 and December 31, 2022. The Company completed testing of its internally-developed software application (“QHSLab platform”) at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During the three months ended September 30, 2023 and 2022 there was $ 18,616 of amortization recognized. During the nine months ended September 30, 2023 and 2022 there was $ 55,848 and $ 37,231 of amortization recognized, respectively. There were no impairments recognized during the nine months ended September 30, 2023 and the year ended December 31, 2022.
Intangible Assets	Intangible Assets Business Combination, Related Issues, Initial Measurement Intangibles, General Intangibles Other Than Goodwill Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances may result in an impact to the value of the assets.
Convertible Notes Payable	Convertible Notes Payable Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
Revenue Recognition	Revenue Recognition Revenue from Contracts with Customers To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract(s); and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products. The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (“SaaS”) agreements whereby the Company provides physicians’ practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term. The Company provides administrative, billing and support services utilizing the Company’s internally-developed software. Revenue is recognized each month based on actual services provided during that month. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.
Research and Development	Research and Development 45,419 48,405 169,489 135,998
Stock-based Compensation	Stock-based Compensation Share Based Payment
Earnings Per Common Share	Earnings Per Common Share
Income Taxes	Income Taxes Accounting for Income Taxes, The Company has net operating losses of $ 3,896,621 begin to expire in 2027
Recently Issued Accounting Standards	Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments This Quarterly Report on Form 10-Q does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company’s financial condition, results of operations, cash flows or disclosures.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Schedule of Indefinite-Lived Intangible Assets U.S. Method Patent 13.4 Web Domain Indefinite life Trademark Indefinite life

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2023
Credit Loss [Abstract]
Schedule of Accounts Receivable	Schedule of Accounts Receivable September 30, December 31, Accounts receivable $ 97,772 $ 55,964 Allowance for doubtful accounts (14,222 ) (8,230 ) Accounts receivable, net $ 83,550 $ 47,734

Capitalized Software and Inta_2

Capitalized Software and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Non-current assets consist of the following at September 30, 2023 and December 31, 2022: Schedule of Intangible Assets Estimated Useful Life (in years) September 30, December 31, Capitalized software 3.0 $ 223,390 $ 223,390 Accumulated amortization (111,695 ) (55,847 ) Capitalized software, net $ 111,695 $ 167,543 Intangible Assets: U.S. Method Patent 13.4 $ 967,500 $ 967,500 Web Domain N/A 161,250 161,250 Trademark N/A 483,750 483,750 Total Intangible assets $ 1,612,500 $ 1,612,500 Accumulated amortization (162,252 ) (108,168 ) Intangible assets, net $ 1,450,248 $ 1,504,332

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable at September 30, 2023 and December 31, 2022, consist of the following: Schedule of Convertible Notes Payable September 30, 2023 December 31, 2022 Note 1 – Shareholder $ 100,000 $ 100,000 Note 2 – Mercer Note 706,000 706,000 Note 3 – Mercer Note #2 440,000 440,000 Total 1,246,000 1,246,000 Debt discount and issuance costs - (84,082 ) Total convertible notes payable 1,246,000 1,161,918 Less: current portion 1,246,000 1,161,918 Non-current portion $ - $ -

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share	Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share 2023 2022 2023 2022 Three Months Ended Nine Months Ended 2023 2022 2023 2022 Stock options 1,100,000 1,100,000 1,100,000 1,100,000 Stock warrants 1,494,854 1,576,647 1,494,854 1,576,647 Total shares excluded from calculation 2,594,854 2,676,647 2,594,854 2,676,647 Antidilutive securities 2,594,854 2,676,647 2,594,854 2,676,647

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Options Outstanding and Exercisable	Options outstanding at September 30, 2023 consist of: Schedule of Options Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date March 12, 2020 500,000 500,000 $ 0.40 March 12, 2025 June 27, 2020 150,000 150,000 $ 0.40 June 27, 2025 January 1, 2021 450,000 450,000 $ 0.65 December 31, 2025 Total 1,100,000 1,100,000
Schedule of Warrants Outstanding and Exercisable	Warrants outstanding at September 30, 2023 consist of: Schedule of Warrants Outstanding and Exercisable Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date August 10, 2021 930,000 930,000 $ 1.25 August 9, 2024 February 23, 2022 14,854 14,854 $ 0.705 February 22, 2024 July 19, 2022 550,000 550,000 $ 0.50 July 18, 2025 Total 1,494,854 1,494,854

Schedule of Indefinite-Lived In

Schedule of Indefinite-Lived Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2023
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Impaired intangible asset	Indefinite life
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Product Information [Line Items]
Capitalized Computer Software, Gross	$ 223,390		$ 223,390		$ 223,390
Capitalized Computer Software, Amortization	18,616		55,848	$ 37,231
Capitalized Computer Software, Impairments					$ 0
Research and development expense	45,419	$ 48,405	169,489	$ 135,998
Operating loss carryforwards	$ 3,896,621		$ 3,896,621
Net operating losses carryforwards, expire date			begin to expire in 2027
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			18.90%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			14.20%

Schedule of Accounts Receivable

Schedule of Accounts Receivable (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Credit Loss [Abstract]
Accounts receivable	$ 97,772	$ 55,964
Allowance for doubtful accounts	(14,222)	(8,230)
Accounts receivable, net	$ 83,550	$ 47,734

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Capitalized software	$ 223,390	$ 223,390
Accumulated amortization	(111,695)	(55,847)
Capitalized software, net	111,695	167,543
Intangible Assets:
Total Intangible assets	1,612,500	1,612,500
Accumulated amortization	(162,252)	(108,168)
Intangible assets, net	$ 1,450,248	1,504,332
Computer Software, Intangible Asset [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	3 years
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, amortization method	13 years 4 months 24 days
Intangible Assets:
Total Intangible assets	$ 967,500	967,500
Web Domain [Member]
Intangible Assets:
Total Intangible assets	161,250	161,250
Trademarks [Member]
Intangible Assets:
Total Intangible assets	$ 483,750	$ 483,750

Capitalized Software and Inta_3

Capitalized Software and Intangible Assets (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 23, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Capitalized Computer Software, Accumulated Amortization		$ 111,695		$ 111,695		$ 55,847
Capitalized Computer Software, Amortization		18,616		55,848	$ 37,231
Capitalized Computer Software, Impairments						$ 0
Acquired intangible assets	$ 1,612,500
Amortization expense		$ 18,028	$ 18,028	$ 54,084	$ 54,084

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Apr. 21, 2023	Sep. 30, 2023	Dec. 31, 2022	Jun. 23, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt default long term debt amount		$ 386,735	$ 426,451
Proceeds from loan	$ 162,000
Payments for loan	$ 20,538
Loan payable maturity date	October 2024
Loan payable		$ 40,821
Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument face amount				$ 750,000

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2023	Jul. 27, 2023	Jul. 19, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Total	$ 1,246,000			$ 1,246,000
Debt discount and issuance costs				(84,082)
Total convertible notes payable	1,246,000			1,161,918
Less: current portion	1,246,000			1,161,918
Non-current portion
Convertible Notes Payable One [Member] | Note 1 – Shareholder [Member]
Short-Term Debt [Line Items]
Total	100,000			100,000
Convertible Notes Payable Two [Member] | Note 2 – Mercer Note [Member]
Short-Term Debt [Line Items]
Total	706,000			706,000
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member]
Short-Term Debt [Line Items]
Total	$ 440,000	$ 440,000	$ 440,000	$ 440,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)						3 Months Ended
	Jul. 27, 2022	Jul. 19, 2022	Nov. 11, 2021	Aug. 10, 2021	May 07, 2021	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Jul. 27, 2023	Jul. 19, 2023	Dec. 31, 2022	Oct. 17, 2022	Aug. 10, 2022
Short-Term Debt [Line Items]
Conversion of notes payable						$ 50,000	$ 27,925
Convertible notes payable								$ 1,246,000			$ 1,246,000
Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount			$ 806,000
Debt instrument convertible conversion price per share			$ 0.65
Conversion of notes payable			$ 50,000
Conversion of notes payable, shares			76,923
Convertible Notes Payable One [Member] | Note 1 – Shareholder [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount					$ 100,000
Debt instrument interest rate stated percentage					10%
Debt instrument, maturity date					Sep. 30, 2022
Debt instrument, description					The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company’s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of December 31, 2023 at the option of the holder using the same conversion calculation
Interest payable, current								24,000			16,521
Convertible notes payable								100,000			100,000
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument convertible conversion price per share			$ 0.20
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount	$ 806,000			$ 806,000				806,000			806,000	$ 806,000
Debt instrument interest rate stated percentage												5%	5%
Number of securities called by warrants or rights			930,000	930,000
Proceeds from warrant exercises				$ 750,000
Debt instrument convertible conversion price per share													$ 0.65
Warrants term			3 years
Exercise price of warrants or rights			$ 1.25
Convertible Notes Payable Three [Member] | Note 2 – Mercer Note [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount	$ 50,000							706,000
Interest payable, current								78,573			52,171
Debt instrument convertible conversion price per share	$ 0.20		$ 0.20
Conversion of notes payable, shares	250,000
Original issue discount			$ 440,000
Unamortized debt issuance expense								0			0
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member]
Short-Term Debt [Line Items]
Convertible notes payable								440,000	$ 440,000	$ 440,000	440,000
Convertible Notes Payable Three [Member] | Note 3 – Mercer Note #2 [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Interest payable, current											9,764
Convertible Notes Payable [Member] | Note 2 – Mercer Note [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount			$ 806,000
Convertible Notes Payable Four [Member] | Note 3 – Mercer Note #2 [Member] | Securities Purchase Agreement [Member] | Mercer Street Global Opportunity Fund LLC [Member]
Short-Term Debt [Line Items]
Debt instrument, principal amount		$ 440,000
Debt instrument interest rate stated percentage		5%
Interest payable, current								26,219
Proceeds from warrant exercises		$ 400,000
Debt instrument convertible conversion price per share		$ 0.20
Exercise price of warrants or rights		$ 0.50
Warrants issued to purchase of common stock		550,000
Total unamortized debt issuance costs								$ 0			61,836
Remaining debt discount											$ 22,247

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)	Dec. 30, 2021	Sep. 30, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock stated value		$ 0.25
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock stated value		0.0001	$ 0.0001
Debt instrument convertible conversion price per share		$ 0.05
Stated value of shares	$ 0.16
Series A2 Convertible Preferred Shares [Member]
Class of Stock [Line Items]
Stock issued during period, shares	2,644,424
Debt instrument face amount	$ 286,078

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	2,594,854	2,676,647	2,594,854	2,676,647
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,100,000	1,100,000	1,100,000	1,100,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,494,854	1,576,647	1,494,854	1,576,647

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Option One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Mar. 12, 2020
Number Outstanding	500,000
Number Exercisable	500,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Mar. 12, 2025
Option Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jun. 27, 2020
Number Outstanding	150,000
Number Exercisable	150,000
Exercise Price | $ / shares	$ 0.40
Expiration Date	Jun. 27, 2025
Option Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jan. 01, 2021
Number Outstanding	450,000
Number Exercisable	450,000
Exercise Price | $ / shares	$ 0.65
Expiration Date	Dec. 31, 2025
Options Held [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,100,000
Number Exercisable	1,100,000

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Warrant One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Aug. 10, 2021
Number Outstanding	930,000
Number Exercisable	930,000
Exercise Price | $ / shares	$ 1.25
Expiration Date	Aug. 09, 2024
Warrant Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Feb. 23, 2022
Number Outstanding	14,854
Number Exercisable	14,854
Exercise Price | $ / shares	$ 0.705
Expiration Date	Feb. 22, 2024
Warrant Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Date Issued	Jul. 19, 2022
Number Outstanding	550,000
Number Exercisable	550,000
Exercise Price | $ / shares	$ 0.50
Expiration Date	Jul. 18, 2025
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number Outstanding	1,494,854
Number Exercisable	1,494,854

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	$ 0	$ 6,000			$ 6,000	$ 23,842
Stock Issued During Period, Value, Issued for Services			$ 3,484	$ 3,484
Options exercised, forfeited or cancelled					0
Options granted					0	0
Outstanding options, shares	1,100,000				1,100,000
Warrants outstanding	81,793				81,793
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock Issued During Period, Value, Issued for Services					$ 0	$ 6,968

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 09, 2021	Sep. 30, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other current liabilities		$ 159,395	$ 116,774
Factoring Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Agreement term	1 year
Advances on sale on receivables	$ 150,000
Reserve of purchased receivables, percentage	10%
Factoring fees, percentage	1.80%
Other current liabilities			$ 3,098

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)				3 Months Ended
	Oct. 04, 2024	Oct. 05, 2023	Apr. 21, 2023	Sep. 30, 2022	Mar. 31, 2022
Subsequent Event [Line Items]
Conversion of notes payable				$ 50,000	$ 27,925
Proceeds from loan			$ 162,000
Payments for loan			$ 20,538
Loan payable maturity date			October 2024
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from loan		$ 226,700
Payments for loan		$ 28,463
Loan payable maturity date		April 2025
Forecast [Member] | Secured Convertible Promissory Note [Member]
Subsequent Event [Line Items]
Conversion of notes payable	$ 10,500
Debt instrument, principal amount	$ 806,000
Conversion of notes payable, shares	420,000
Debt instrument convertible conversion price per share	$ 0.025